RecruitingNCT02434393

Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

Characterizing Cognitive Decline in Late Life Depression: The Alzheimer's Disease Neuroimaging Initiative - Depression Project


Sponsor

University of Southern California

Enrollment

120 participants

Start Date

Mar 4, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison. Depression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.


Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is following up with older adults who participated in a previous research project on late-life depression and memory decline, to continue monitoring how thinking and memory change over time and whether brain scan findings help predict those changes. **You may be eligible if...** - You previously participated in the original "Characterizing Cognitive Decline in Late Life Depression" study or the related MRI psychotherapy response study - If you are taking an antidepressant, your dose has been stable for at least 4 weeks before the MRI scan - If you are in psychotherapy, you have completed at least 4 weeks of treatment before the scan - You may be taking memory-enhancing medications and still participate **You may NOT be eligible if...** - You did not participate in either of the two qualifying predecessor studies Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

University of California, San Francisco

San Francisco, California, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02434393


Related Trials